Basilea Pharmaceutica International Ltd. is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines for the treatment of serious infectious diseases and oncology indications.
Headquartered in Basel, Switzerland, the company was established to address unmet medical needs in areas such as antifungal and antibacterial therapies. Its flagship product, Cresemba (isavuconazonium sulfate), is an antifungal medication approved for the treatment of invasive aspergillosis and mucormycosis in adults and has been licensed to partners for global distribution.
Basilea operates through a combination of in-house development and strategic partnerships, with a presence in Europe and collaborations extending to other regions including Japan, as evidenced by licensing agreements for clinical trials. The company is publicly listed and positions itself as a specialist in anti-infective and oncology pharmaceuticals within the broader pharmaceutical industry. Additionally, the company explores oncology treatments, positioning it as a diversified player in the pharmaceutical sector focused on high-need therapeutic areas.
Also known as Basilea Pharmaceutica Ltd. and Basilea Pharmaceutica.
Phase II study in Japanese children (1–17 years) to evaluate safety and pharmacokinetics of isavuconazonium sulfate for invasive fungal infections.
